Cadrenal Therapeutics, Inc. (CVKD) Historical Stock Prices
Cadrenal Therapeutics, Inc. (CVKD) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: CVKD
CIK: 1937993
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
WithumSmith+Brown, PC
Auditor SinceSince 6/30/2022 12:00:00 AM
Lead Engagement PartnerPatrick Donahue
Audit LocationEast Brunswick, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-13 | 2026-10-09 | OWNERSHIP DOCUMENT | 0001213900-26-109132 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-09 | OWNERSHIP DOCUMENT | 0001213900-26-109131 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-09 | OWNERSHIP DOCUMENT | 0001213900-26-109130 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-09 | OWNERSHIP DOCUMENT | 0001213900-26-109129 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-09 | OWNERSHIP DOCUMENT | 0001213900-26-109124 | View SEC Doc Filr Page |
| S-8 | 2026-10-08 | — | REGISTRATION STATEMENT | 0001213900-26-108052 | View SEC Doc Filr Page |
| 8-K | 2026-10-07 | 2026-10-07 | CURRENT REPORT | 0001213900-26-107442 | View SEC Doc Filr Page |
| 8-K | 2026-09-29 | 2026-09-24 | CURRENT REPORT | 0001213900-26-104647 | View SEC Doc Filr Page |
| S-8 | 2026-09-03 | — | REGISTRATION STATEMENT | 0001213900-26-097282 | View SEC Doc Filr Page |
| 8-K | 2026-08-31 | 2026-08-31 | CURRENT REPORT. | 0001213900-26-095394 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-089153 | View SEC Doc Filr Page |
| 8-K | 2026-08-13 | 2026-08-13 | CURRENT REPORT | 0001213900-26-089147 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0001193125-26-339234 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-03 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-26-084716 | View SEC Doc Filr Page |
| ARS | 2026-08-03 | 2025-12-31 | FORM ARS | 0001213900-26-084713 | View SEC Doc Filr Page |
| DEF 14A | 2026-08-03 | 2026-09-24 | PROXY STATEMENT | 0001213900-26-084710 | View SEC Doc Filr Page |
| PRE 14A | 2026-07-23 | 2026-07-23 | PROXY STATEMENT | 0001213900-26-081012 | View SEC Doc Filr Page |
| 8-K | 2026-07-21 | 2026-07-21 | CURRENT REPORT | 0001213900-26-079824 | View SEC Doc Filr Page |
| EFFECT | 2026-07-20 | — | EFFECT Filing | 9999999995-26-002367 | View SEC Doc Filr Page |
| 424B3 | 2026-07-20 | — | PROSPECTUS | 0001213900-26-079648 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-14 | CURRENT REPORT | 0001213900-26-079176 | View SEC Doc Filr Page |
| D | 2026-07-15 | — | D Filing | 0001213900-26-078373 | View SEC Doc Filr Page |
| S-3 | 2026-07-13 | — | REGISTRATION STATEMENT | 0001213900-26-077647 | View SEC Doc Filr Page |
| 8-K | 2026-07-10 | 2026-07-07 | CURRENT REPORT | 0001213900-26-077134 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-06-29 | 4 Filing | 0001213900-26-074557 | View SEC Doc Filr Page |